Hoffmann-la Roche Inc.

F. Hoffmann-la Roche Ag

Buelent Kocer

Bernd Kuhn

Hans G Richter

Uwe Grether

Benoit Hornsperger

Joerg Benz

Stephen Deems Gabriel

Wei Zhu

Bernd Buettelmann

Hong Shen

Satoshi Tsuchiya

Taishan Hu

Lei Guo

Mingwei Zhou

Guolong Wu

Steven Joseph Berthel

Xianfeng Lin

Haixia Liu

Yan Lou

Luca Claudio Gobbi

Jean-Marc Plancher

Francisco Javier Lopez-Tapia

Markus Rudolph

Timothy D Owens

Fariborz Firooznia

Peter Michael Wovkulich

Elbert Chin

Roland Joseph Billedeau

Eric Mertz

Christine E Brotherton-Pleiss

Fionn O'Hara

Zhisen Zhang

Saul Jaime-Figueroa

Buyu Kou

Katrin Groebke Zbinden

Shawn David Erickson

Alexander Mayweg

Lisha Wang

Weixing Zhang

Qingjie Ding

Jing Zhang

Nan Jiang

Didier Rombach

Robert James Weikert

Dennis Jul Hansen

Martin Ritter

Yimin Hu

Marco Prunotto

Charles Bell

Jenny Tan

Zhi Chen

Xiaochun Han

Houguang Shi

Lucja Orzechowski

Alexander Lee Satz

Ramona Hilgenkamp

Feng Chi

Carsten Kroll

Guozhi Tang

Shixiang Yan

Qiang Zhang

Zongxing Qiu

Gangqin Li

Joseph Anthony Bilotta

Marius Daniel Rinaldo Lutz

Martin Kuratli

Hans Richter

Xiang Wu

Xiaofei Yan

Ann Petersen

Yangcheng Qiu

Rui Chen

Ludovic Collin

Simon E Johnson

David Shawn Erickson

Robert J Weikert

Fionn O`hara

The invention provides new heterocyclic compounds having the general formula (I) wherein A, L, X, m, n, Rand Rare as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.

Heterocyclic compounds as monoacylglycerol lipase inhibitors

The invention provides new heterocyclic compounds having the general formula (Ie) wherein R, Rand Rare as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.

Octahydropyrido[1,2-alpha]pyrazines as MAGL inhibitors

The invention provides new heterocyclic compounds having the general formula (IA) wherein A, L, X, Y, m, n, Rand Rare as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.

Heterocyclic compounds

The invention provides new heterocyclic compounds having the general Formula (I), or a pharmaceutically acceptable salt thereof, 

Piperazine derivatives as MAGL inhibitors

The present invention relates to compounds of formula (I): 

Spiroindolinones as DDR1 inhibitors

Triaza-spirodecanones as DDR1 inhibitors

The invention provides novel compounds having the general formula: wherein R, R, Rand Rare as defined in the description and in the claims, as well as or pharmaceutically acceptable salts, or tautomerism isomers, or enantiomers, or diastereomers thereof. The invention also contains compositions including the compounds and methods of using the compounds.

6-bridged heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection

The present invention discloses compounds of Formula I: wherein the variables in Formula I are defined as described herein. Also disclosed are pharmaceutical compositions containing such compounds and methods for using the compounds of Formula I in the prevention or treatment of HCV infection. 

Antiviral compounds

The present invention discloses compounds of Formula (I): wherein the variables in Formula (I) are defined as described herein. Also disclosed are pharmaceutical compositions containing such compounds and methods for using the compounds of Formula (I) in the prevention or treatment of HCV infection. 

The invention provides novel compounds having the general formula: wherein R, R, R, Rand A are as described herein, compositions including the compounds and methods of using the compounds.

6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection

This application discloses 6-(2-Hydroxymethyl-phenyl)-2-methyl-2H-pyridazin-3-one derivatives according to generic Formula I: wherein, variables X, R, and Y, are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation, such as rheumatoid arthritis. Also disclosed are compositions containing compounds of Formula I and at least one carrier, diluent or excipient.

Inhibitors of bruton's tyrosine kinase

Growing community of inventors

Basel, Switzerland

Buelent Kocer